200,000+ products from a single source!
sales@angenechem.com
138844-81-2 | Phosphonic acid, P,P'-[1-hydroxy-3-(methylpentylamino)propylidene]bis-, sodium salt (1:1)
CAS No: 138844-81-2 Catalog No: AG0019OO MDL No:MFCD07197214
Product Description
Catalog Number:
AG0019OO
Chemical Name:
Phosphonic acid, P,P'-[1-hydroxy-3-(methylpentylamino)propylidene]bis-, sodium salt (1:1)
CAS Number:
138844-81-2
Molecular Formula:
C9H22NNaO7P2
Molecular Weight:
341.2108
MDL Number:
MFCD07197214
IUPAC Name:
sodium;hydroxy-[1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphinate
InChI:
InChI=1S/C9H23NO7P2.Na/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17;/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17);/q;+1/p-1
InChI Key:
LXLBEOAZMZAZND-UHFFFAOYSA-M
SMILES:
CCCCCN(CCC(P(=O)(O)O)(P(=O)(O)[O-])O)C.[Na+]
UNII:
23Y0B94E49
Properties
Complexity:
377
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
2
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
341.077g/mol
Formal Charge:
0
Heavy Atom Count:
20
Hydrogen Bond Acceptor Count:
8
Hydrogen Bond Donor Count:
4
Isotope Atom Count:
0
Molecular Weight:
341.212g/mol
Monoisotopic Mass:
341.077g/mol
Rotatable Bond Count:
9
Topological Polar Surface Area:
141A^2
Undefined Atom Stereocenter Count:
1
Undefined Bond Stereocenter Count:
0
Literature
| Title | Journal |
|---|---|
| Bioactivity of Ti-6Al-4V alloy implants treated with ibandronate after the formation of the nanotube TiO2 layer. | Journal of biomedical materials research. Part B, Applied biomaterials 20121101 |
| Incidence of maxillary sinusitis and oro-antral fistulae in bisphosphonate-related osteonecrosis of the jaw. | Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery 20121001 |
| Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial. | The Journal of clinical endocrinology and metabolism 20121001 |
| Oral bisphosphonate-related osteonecrosis of the jaws: Clinical characteristics of a series of 20 cases in Spain. | Medicina oral, patologia oral y cirugia bucal 20120901 |
| Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates. | Journal of bone and mineral metabolism 20120901 |
| Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes. | Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20120801 |
| Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial. | Scandinavian journal of rheumatology 20120801 |
| Monitoring of bone turnover markers does not improve persistence with ibandronate treatment. | Joint, bone, spine : revue du rhumatisme 20120701 |
| Bisphosphonate-related osteonecrosis of the mandible secondary to postural pressure. | Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20120701 |
| Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population. | Arthritis care & research 20120701 |
| Once-monthly oral ibandronate treatment in an adolescent with recurrent fractures and inadequately low bone mass. | Journal of paediatrics and child health 20120701 |
| Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120601 |
| Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120601 |
| Gastrointestinal bleeding following intravenous ibandronate administration. | Journal of pharmacy practice 20120601 |
| Monthly ibandronate for the prevention of bone loss in patients after liver transplantation. | Transplantation proceedings 20120601 |
| Successful treatment of calcific uraemic arteriolopathy with bisphosphonates. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20120514 |
| [Simultaneous determination of alendronate, pamidronate, ibandronate and risedronate using ion chromatography with integrated pulsed amperometric detection]. | Se pu = Chinese journal of chromatography 20120401 |
| Effect of dosing interval duration of intermittent ibandronate treatment on the healing process of femoral osteotomy in a rat fracture model. | Calcified tissue international 20120301 |
| Phase I clinical study to select a novel oral formulation for ibandronate containing the excipient sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC). | Die Pharmazie 20120301 |
| Question: In postmenopausal women with osteoporosis is once monthly oral ibandronate (150 mg) therapy preferred to once weekly oral bisphosphonate therapy. | The Journal of the Oklahoma State Medical Association 20120301 |
| Ibandronate and calcitriol reduces fracture risk, reverses bone loss, and normalizes bone turnover after LTX. | Transplantation 20120215 |
| Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro. | Clinical oral investigations 20120201 |
| Counting touching cell nuclei using fast ellipse detection to assess in vitro cell characteristics: a feasibility study. | Clinical oral investigations 20120201 |
| The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes--in vitro study. | Clinical oral investigations 20120201 |
| Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion. | Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20120201 |
| [Pelvic pain in the athlete: not always that simple...]. | Revue medicale suisse 20120125 |
| Effect of monthly ibandronate on hip structural geometry in men with low bone density. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120101 |
| Impact of oral ibandronate 150 mg once monthly on bone structure and density in post-menopausal osteoporosis or osteopenia derived from in vivo μCT. | Bone 20120101 |
| Possible role of oral ibandronate administration in Osteonecrosis of the Jaw: a case report. | International journal of immunopathology and pharmacology 20120101 |
| Pathogenesis and bisphosphonate treatment of skeletal events and bone pain in metastatic cancer: focus on ibandronate. | Onkologie 20120101 |
| Phase II study of loading-dose ibandronate treatment in patients with breast cancer and bone metastases suffering from moderate to severe pain. | Onkologie 20120101 |
| Impact of long-term cinacalcet, ibandronate or teriparatide therapy on bone mineral density of hemodialysis patients: a pilot study. | American journal of nephrology 20120101 |
| Bisphosphonates for osteoporosis in primary biliary cirrhosis. | The Cochrane database of systematic reviews 20111207 |
| Daily or monthly ibandronate prevents or restores deteriorations of bone mass, architecture, biomechanical properties and markers of bone turnover in androgen-deficient aged rats. | The aging male : the official journal of the International Society for the Study of the Aging Male 20111201 |
| Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner--a quantitative in vitro gene expression analysis of Dlx5, Runx2, OCN, MSX1 and MSX2. | Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery 20111201 |
| Renal safety of ibandronate 6 mg infused over 15 min versus 60 min in breast cancer patients with bone metastases: a randomized open-label equivalence trial. | Breast (Edinburgh, Scotland) 20111201 |
| Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease--the DIVINE study. | Bone 20111201 |
| Monthly or weekly bisphosphonate? Evaluation of satisfaction in patients with postmenopausal osteoporosis using OPSAT-Q questionnaire during the BOOSTER study in Croatia. | Clinical rheumatology 20111201 |
| Integrated model for denosumab and ibandronate pharmacodynamics in postmenopausal women. | Biopharmaceutics & drug disposition 20111101 |
| The GISS trial: a phase II prevention trial of screening plus goserelin, ibandronate, versus screening alone in premenopausal women at increased risk of breast cancer. | Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20111001 |
| Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost. | Journal of managed care pharmacy : JMCP 20111001 |
| Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study. | Anticancer research 20111001 |
| Benefit of infusions with ibandronate treatment in children with osteogenesis imperfecta. | Chinese medical journal 20111001 |
| Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis. | American journal of therapeutics 20110901 |
| A comparative study of intravenous ibandronate and pamindronate in patients with bone metastases from breast or lung cancer: effect on metastatic bone pain. | American journal of therapeutics 20110901 |
| Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials. | The Korean journal of internal medicine 20110901 |
| Administration of sodium ibandronate in the treatment of complicated giant cell tumor of the spine. | Spine 20110801 |
| Non-surgical management of stage 3 biphosphonate-related oroantral fistula. | The British journal of oral & maxillofacial surgery 20110701 |
| Effect of bisphosphonates on anodized and heat-treated titanium surfaces: an animal experimental study. | Journal of periodontology 20110701 |
| [Assessment of volumetric bone mineral density and geometry for hip with clinical CT device]. | Clinical calcium 20110701 |
| Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer. | International journal of clinical oncology 20110601 |
| Intravenous bisphosphonates for post-menopausal osteoporosis: adherence to a network guideline. | Journal of clinical pharmacy and therapeutics 20110601 |
| Intravenous ibandronate or sodium-fluoride--a 3.5 years study on bone density and fractures in Crohn's disease patients with osteoporosis. | Journal of gastrointestinal and liver diseases : JGLD 20110601 |
| Commentary on an article by Jacob S. Vandermeer et al.: 'Local administration of ibandronate and bone morphogenetic protein-2 after ischemic osteonecrosis of the immature femoral head. A combined therapy that stimulates bone formation and decreases femoral head deformity'. | The Journal of bone and joint surgery. American volume 20110518 |
| Local administration of ibandronate and bone morphogenetic protein-2 after ischemic osteonecrosis of the immature femoral head: a combined therapy that stimulates bone formation and decreases femoral head deformity. | The Journal of bone and joint surgery. American volume 20110518 |
| Ibandronate does not reduce the anabolic effects of PTH in ovariectomized rat tibiae: a microarchitectural and mechanical study. | Bone 20110501 |
| Low-magnitude high-frequency vibration (LMHFV) enhances bone remodeling in osteoporotic rat femoral fracture healing. | Journal of orthopaedic research : official publication of the Orthopaedic Research Society 20110501 |
| Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110301 |
| Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro. | Oral diseases 20110301 |
| Bone mineral disease in children after renal transplantation in steroid-free and steroid-treated patients--a prospective study. | Pediatric transplantation 20110301 |
| Treatment of lumbar pars interarticularis stress injuries in athletes with intravenous bisphosphonates: five case studies. | Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine 20110301 |
| The treatment of symptomatic osteoporotic spinal compression fractures. | The Journal of the American Academy of Orthopaedic Surgeons 20110301 |
| Stability indicating ion chromatography method for the simultaneous determination of ibandronate sodium drug substance and its impurities. | Journal of pharmaceutical and biomedical analysis 20110220 |
| Osteonecrosis of the jaw and the role of macrophages. | Journal of the National Cancer Institute 20110202 |
| Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. | Clinical oral investigations 20110201 |
| Bisphosphonates inhibit phosphorylation of signal transducer and activator of transcription 3 and expression of suppressor of cytokine signaling 3: implications for their effects on innate immune function and osteoclastogenesis. | Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20110201 |
| Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D. | World journal of gastroenterology 20110121 |
| Ibandronate promotes osteogenic differentiation of periodontal ligament stem cells by regulating the expression of microRNAs. | Biochemical and biophysical research communications 20110107 |
| Differential effects of ibandronate, docetaxel and farnesol treatment alone and in combination on the growth of prostate cancer cell lines. | Acta oncologica (Stockholm, Sweden) 20110101 |
| Ibandronate affects bone growth and mineralization in rats with normal and reduced renal function. | Pediatric nephrology (Berlin, Germany) 20110101 |
| [Ibandronate]. | Clinical calcium 20110101 |
| When do bisphosphonates make the most sense? | The Journal of family practice 20110101 |
| The role of i.v. ibandronate administration in osteoporosis therapy. | Endokrynologia Polska 20110101 |
| Adverse cutaneous drug reactions to ibandronate. | European journal of dermatology : EJD 20110101 |
| [The role of i.v. ibandronate administration in osteoporosis therapy]. | Endokrynologia Polska 20110101 |
| [Osteonecrosis of the jaw associated with oral treatment with ibandronate]. | Anales del sistema sanitario de Navarra 20110101 |
| Drug-drug interaction study between a novel oral ibandronate formulation and metformin. | Arzneimittel-Forschung 20110101 |
| Prospective clinical study of once monthly ibandronate in the treatment of osteoporosis and prevention of fractures in postmenopausal women: ORPHEUM Study. | Srpski arhiv za celokupno lekarstvo 20110101 |
| Adherence to bisphosphonate therapy in postmenopausal osteoporotic women. | Folia medica 20110101 |
| Preparation and properties of new co-crystals of ibandronate with gluco- or galactopyranoside derivatives. | Molecules (Basel, Switzerland) 20101208 |
| Outcome of patients with early breast cancer receiving nitrogen-containing bisphosphonates: a comparative analysis from the Metropolitan Detroit Cancer Surveillance System. | Clinical breast cancer 20101201 |
| Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism. | Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20101101 |
| Bilateral simultaneous femoral diaphyseal fractures in a patient with long-term ibandronate use. | Orthopedics 20101011 |
| Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study. | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20101001 |
| Enzyme-linked immunosorbent serum assays (ELISAs) for rat and human N-terminal pro-peptide of collagen type I (PINP)--assessment of corresponding epitopes. | Clinical biochemistry 20101001 |
| Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate. | Calcified tissue international 20101001 |
| The increased expression of receptor activator of nuclear-kappaB ligand (RANKL) of multiple myeloma bone marrow stromal cells is inhibited by the bisphosphonate ibandronate. | Journal of cellular biochemistry 20100901 |
| Successful treatment of SAPHO syndrome with ibandronate. | Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20100801 |
| Treatment of osteoporosis after liver transplantation with ibandronate. | Transplant international : official journal of the European Society for Organ Transplantation 20100701 |
| Longitudinal change in clinical fracture incidence after initiation of bisphosphonates. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20100601 |
| Regional distribution of spine and hip QCT BMD responses after one year of once-monthly ibandronate in postmenopausal osteoporosis. | Bone 20100601 |
| Postmenopausal osteoporosis: another approach to management. | The Journal of family practice 20100601 |
| [Monthly ibandronate attachment to Mexican and Chilean women with osteoporosis, with or without a biofeedback strategy]. | Ginecologia y obstetricia de Mexico 20100601 |
| An in vitro assay to measure targeted drug delivery to bone mineral. | ChemMedChem 20100503 |
| Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study. | Journal of bone and mineral metabolism 20100501 |
| Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials. | International journal of clinical practice 20100501 |
| How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care. | Journal of the American Dental Association (1939) 20100501 |
| Efficacy and safety of monthly ibandronate in men with low bone density. | Bone 20100401 |
| Synthesis and preliminary pharmacological characterisation of a new class of nitrogen-containing bisphosphonates (N-BPs). | Bioorganic & medicinal chemistry 20100401 |
| Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study. | Bone 20100301 |
| Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc analysis from DIVA. | Current medical research and opinion 20100301 |
| Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study. | Journal of medical economics 20100301 |
| Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. | Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20100201 |
| Oral ibandronate in metastatic bone breast cancer: the Florence University experience and a review of the literature. | Journal of chemotherapy (Florence, Italy) 20100201 |
| Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20100101 |
| Management of symptomatic bone metastases from breast cancer with concomitant use of external radiotherapy and ibandronate: results of a prospective, pilot study. | The breast journal 20100101 |
| The utility of changes in serum levels of C-terminal telopeptide of type I collagen in predicting patient response to oral monthly ibandronate therapy. | Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 20100101 |
| Efficacy and safety of once monthly ibandronate treatment in patients with reduced bone mineral density--ESTHER study. | Srpski arhiv za celokupno lekarstvo 20100101 |
| Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review. | Journal of cancer research and therapeutics 20100101 |
| Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption--implications for osteoclast quality. | BMC musculoskeletal disorders 20100101 |
| Challenges in clinical patient management. | Cancer investigation 20100101 |
| Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes. | Onkologie 20100101 |
| Health-related quality of life among patients with postmenopausal osteoporosis treated with weekly and monthly bisphosphonates. | Endocrine research 20100101 |
| Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoid. | Arthritis research & therapy 20100101 |
| Bisphosphonates in calcific aortic stenosis: association with slower progression in mild disease--a pilot retrospective study. | Cardiology 20100101 |
| The efficiency of Bonviva (Ibadronate) in women with pre-post menopause. | Medicinski arhiv 20100101 |
| Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphanates. | Prilozi 20100101 |
| Apoptosis-mediated cytotoxic effects of ibandronic acid on hormone- and drug-refractory prostate cancer cells and human breast cancer cells. | The Journal of international medical research 20100101 |
| Metronomic administration of ibandronate and its anti-angiogenic effects in vitro. | Microvascular research 20091201 |
| Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg. | Current medical research and opinion 20091201 |
| Review of osteoporosis pharmacotherapy for geriatric patients. | The American journal of geriatric pharmacotherapy 20091201 |
| Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091110 |
| Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer. | European journal of cancer care 20091101 |
| Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women. | Calcified tissue international 20091101 |
| A retrospective clinical and radiographic study on healing of periradicular lesions in patients taking oral bisphosphonates. | Journal of endodontics 20091101 |
| High-throughput HPLC-MS/MS method to determine ibandronate in human plasma for pharmacokinetic applications. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091001 |
| [Anti-fracture efficacy of intravenous ibandronate: how to translate epidemiological studies into daily clinical practice]. | Revue medicale de Liege 20091001 |
| Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20090901 |
| Ibandronate reduces endogenous reactive oxygen species levels in cultured prostate cancer and endothelial cells. | Microvascular research 20090901 |
| Ibandronate: a review of its vertebral and nonvertebral antifracture efficacy. | Women's health (London, England) 20090901 |
| Tolerability of dose escalation of ibandronate in patients with multiple myeloma and end-stage renal disease: a case series. | Onkologie 20090901 |
| [Emergencies in hematology and oncology]. | Deutsche medizinische Wochenschrift (1946) 20090901 |
| [Diagnosis and treatment of bone marrow edema syndrome of the hip and differential diagnosis from avascular necrosis of femoral head]. | Zhongguo gu shang = China journal of orthopaedics and traumatology 20090901 |
| Safety and antisorptive power of Ibandronate applied in the real-life setting. | Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20090901 |
| Impact of bone marker feedback on adherence to once monthly ibandronate for osteoporosis among Asian postmenopausal women. | International journal of rheumatic diseases 20090901 |
| Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy. | Current medical research and opinion 20090801 |
| Pricey osteoporosis remedy doesn't beat older drugs. | Consumer reports 20090801 |
| Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20090701 |
| Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate. | Journal of women's health (2002) 20090701 |
| Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review. | Clinical therapeutics 20090701 |
| Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review. | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20090601 |
| Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study. | Bone 20090501 |
| Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates. | Southern medical journal 20090501 |
| [Drugs under development for osteoporosis ]. | Nihon rinsho. Japanese journal of clinical medicine 20090501 |
| Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate. | The Annals of pharmacotherapy 20090401 |
| Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. | Clinical therapeutics 20090401 |
| Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss. | Bone 20090301 |
| Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: results from the Croatian PROMO Study. | Clinical rheumatology 20090301 |
| Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis. | Bone 20090301 |
| The effect of surface immobilized bisphosphonates on the fixation of hydroxyapatite-coated titanium implants in ovariectomized rats. | Biomaterials 20090301 |
| Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20090201 |
| Plain film and CBCT findings in a case of bisphosphonate-related osteonecrosis of the jaw. | Quintessence international (Berlin, Germany : 1985) 20090201 |
| Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. | The American journal of medicine 20090201 |
| Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. | Cancer investigation 20090201 |
| Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis. | The Journal of clinical endocrinology and metabolism 20090101 |
| Oral ibandronate preserves trabecular microarchitecture: micro-computed tomography findings from the oral iBandronate Osteoporosis vertebral fracture trial in North America and Europe study. | Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 20090101 |
| [New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates]. | Clinical calcium 20090101 |
| Identification of secondary targets of N-containing bisphosphonates in mammalian cells via parallel competition analysis of the barcoded yeast deletion collection. | Genome biology 20090101 |
| Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment. | Clinical interventions in aging 20090101 |
| Is there a role for ibandronate in the treatment of prostate cancer patients with bony metastases? | Acta oncologica (Stockholm, Sweden) 20090101 |
| Dendritic multishell architectures for drug and dye transport. | Journal of controlled release : official journal of the Controlled Release Society 20081218 |
| Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease. | Journal of cancer research and clinical oncology 20081201 |
| Clinical and radiologic response in patients with bone metastases managed with combined radiotherapy and bisphosphonates. | Journal of surgical oncology 20081201 |
| Managing neoplastic bone disease with ibandronic acid: a preclinical and clinical data update. | Expert opinion on pharmacotherapy 20081201 |
| [Bisphosphonates for osseus invasion caused by bronchial carcinoma]. | Deutsche medizinische Wochenschrift (1946) 20081101 |
| Ibandronate: is there an effect on nonvertebral fractures? | Clinical rheumatology 20081001 |
| An open-label pilot trial of ibandronate for complex regional pain syndrome. | The Clinical journal of pain 20081001 |
| Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20081001 |
| [Ibandronate in the treatment of postmenopausal osteoporosis]. | Lege artis medicinae : uj magyar orvosi hirmondo 20081001 |
| Intravenous ibandronate rapidly reduces pain, neurochemical indices of central sensitization, tumor burden, and skeletal destruction in a mouse model of bone cancer. | Journal of pain and symptom management 20080901 |
| Acute phase reaction with intravenous ibandronate. | The American journal of medicine 20080901 |
| Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates. | Current osteoporosis reports 20080901 |
| Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. | The American journal of managed care 20080901 |
| [Update on treatment of postmenopausal osteoporosis]. | Revue medicale de Bruxelles 20080901 |
| Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension. | Clinical rheumatology 20080801 |
| [Daily practice using the guidelines for prevention and treatment of osteoporosis. Evolution of bisphosphonate therapy. Intravenous injection]. | Clinical calcium 20080801 |
| Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study. | Annals of oncology : official journal of the European Society for Medical Oncology 20080701 |
| Identification of novel bone-specific molecular targets of binge alcohol and ibandronate by transcriptome analysis. | Alcoholism, clinical and experimental research 20080701 |
| Oral osteonecrosis associated with the use of ibandronate: report of a case and clinical implications. | Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20080701 |
| Ibandronate in profile: drug characteristics and clinical efficacy. | Expert opinion on drug metabolism & toxicology 20080701 |
| Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety. | Toxicology in vitro : an international journal published in association with BIBRA 20080601 |
| Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. | Postgraduate medical journal 20080601 |
| Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II). | Joint, bone, spine : revue du rhumatisme 20080501 |
| Ibandronate in benign bone disease. | Reviews on recent clinical trials 20080501 |
| Quarterly intravenous ibandronate for postmenopausal osteoporosis. | Women's health (London, England) 20080501 |
| Effects of the bisphosphonate ibandronate on hyperalgesia, substance P, and cytokine levels in a rat model of persistent inflammatory pain. | European journal of pain (London, England) 20080401 |
| Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation. | Clinical therapeutics 20080401 |
| A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy. | Breast cancer research and treatment 20080301 |
| Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20080301 |
| Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands. | Current medical research and opinion 20080301 |
| Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. | The Journal of rheumatology 20080301 |
| [Osteonecrosis of the jaw developing during bisphosphonate treatment]. | Magyar onkologia 20080301 |
| Reply to the article 'oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases' by J.-J. Body et al. (Ann Oncol 2007; 18: 1165-1171). | Annals of oncology : official journal of the European Society for Medical Oncology 20080201 |
| [Prescription of bisphosphonates in prostate cancer]. | Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20080201 |
| Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. | Current medical research and opinion 20080101 |
| Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. | Current medical research and opinion 20080101 |
| Vertebral fracture diagnosis in the multinational BONE study of oral ibandronate: quality management in radiology. | Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 20080101 |
| Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells. | Breast cancer research : BCR 20080101 |
| Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases. | PharmacoEconomics 20080101 |
| Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model. | PharmacoEconomics 20080101 |
| [Cost-effectiveness of oral ibandronate, i.v. zoledronic acid and i.v. generic pamidronate in the management of metastatic bone disease in breast cancer patients: two parallel studies]. | Recenti progressi in medicina 20080101 |
| Rapid suppression of bone resorption marker levels with ibandronate therapy in a bisphosphonate-naïve population. | Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 20080101 |
| Cost-effectiveness of oral clodronate compared with oral ibandronate, intravenous zoledronate or intravenous pamidronate in breast cancer patients. | The Journal of international medical research 20080101 |
| Renal toxicity following zoledronic acid reversed with ibandronate in a prostate cancer patient with bone metastases. | Urologia internationalis 20080101 |
| Ibandronate uptake in the jaw is similar to long bones and vertebrae in the rat. | Journal of bone and mineral metabolism 20080101 |
| Treatment of reduced bone density with ibandronate in dialysis patients. | Journal of nephrology 20080101 |
| Preclinical and clinical efficacy of the bisphosphonate ibandronate in cancer treatment. | Current clinical pharmacology 20080101 |
| Osteonecrosis of the jaw in a patient treated with ibandronate. | Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20080101 |
| [Hypercalcaemic crisis and acute renal failure due to primary hyperparathyroidism]. | Deutsche medizinische Wochenschrift (1946) 20080101 |
| Ibandronate: a review of its use in the management of postmenopausal osteoporosis. | Drugs 20080101 |
| Renal tolerability of intermittent intravenous ibandronate treatment for patients with postmenopausal osteoporosis: a review. | Clinical and experimental rheumatology 20080101 |
| Metastatic ductal eccrine adenocarcinoma masquerading as an invasive ductal carcinoma of the male breast. | Journal of cutaneous pathology 20071201 |
| Evidence based medicine and effective interventions of pharmacological therapy for the prevention of osteoporotic fractures. | Minerva endocrinologica 20071201 |
| Local peroperative treatment with a bisphosphonate improves the fixation of total knee prostheses: a randomized, double-blind radiostereometric study of 50 patients. | Acta orthopaedica 20071201 |
| Linköping University Medical Dissertation No. 1033. Following the mevalonate pathway to bone heal alley. | Acta orthopaedica. Supplementum 20071201 |
| [New bone density conservation agents for osteoporosis under research and development: Ibandronate]. | Nihon rinsho. Japanese journal of clinical medicine 20071128 |
| Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer. | European journal of cancer care 20071101 |
| Progression of efficacy with ibandronate: a paradigm for the development of new bisphosphonates. | Annals of the New York Academy of Sciences 20071101 |
| Vitamin D and ibandronate prevent cancellous bone loss associated with binge alcohol treatment in male rats. | Bone 20071001 |
| Osteoporosis: non-hormonal treatment. | Climacteric : the journal of the International Menopause Society 20071001 |
| [The benefit from ibandronate in the treatment of postmenopausal osteoporosis]. | Vnitrni lekarstvi 20071001 |
| Application of metabonomics in a comparative profiling study reveals N-acetylfelinine excretion as a biomarker for inhibition of the farnesyl pathway by bisphosphonates. | Chemical research in toxicology 20070901 |
| Osteoporosis medication profile preference: results from the PREFER-US study. | Health expectations : an international journal of public participation in health care and health policy 20070901 |
| [Adjuvant therapy of locally advanced prostate carcinoma with ibandronate]. | Der Urologe. Ausg. A 20070901 |
| Renal safety and pharmacokinetics of ibandronate in multiple myeloma patients with or without impaired renal function. | Journal of clinical pharmacology 20070801 |
| Oral bisphosphonate associated osteonecrosis of the jaws: three case reports. | British dental journal 20070728 |
| Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. | Annals of the rheumatic diseases 20070701 |
| Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases. | Annals of oncology : official journal of the European Society for Medical Oncology 20070701 |
| New and emerging treatments for osteoporosis. | Current opinion in rheumatology 20070701 |
| Pharmacological treatment of osteoporosis for people over 70. | Aging clinical and experimental research 20070601 |
| Validation of a capillary electrophoresis method for the analysis of ibandronate related impurities. | Journal of pharmaceutical and biomedical analysis 20070509 |
| Bisphosphonates. A cornerstone of osteoporosis treatment. | Mayo Clinic women's healthsource 20070501 |
| [Nurse's role in the home management of patients with breast cancer and bone metastases]. | Soins; la revue de reference infirmiere 20070501 |
| Ibandronate treatment reverses glucocorticoid-induced loss of bone mineral density and strength in minipigs. | Bone 20070301 |
| Use of intravenous bisphosphonates in osteoporosis. | Current osteoporosis reports 20070301 |
| Prevention and treatment of glucocorticoid-induced osteoporosis. | Current osteoporosis reports 20070301 |
| Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women. | Clinical interventions in aging 20070301 |
| Differential effects of bisphosphonates on breast cancer cell lines. | Cancer letters 20070208 |
| Effects of ibandronate on bone quality: preclinical studies. | Bone 20070201 |
| Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. | Bone 20070201 |
| Drug approvals. | The Nurse practitioner 20070201 |
| Combination ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologic assessment. | International journal of radiation oncology, biology, physics 20070101 |
| Retention, distribution, and effects of intraosseously administered ibandronate in the infarcted femoral head. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20070101 |
| [Therapeutic agents for disorders of bone and calcium metabolism: Ibandronate]. | Clinical calcium 20070101 |
| The bisphosphonate ibandronate accelerates osseointegration of hydroxyapatite-coated cementless implants in an animal model. | Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association 20070101 |
| Preventative ibandronate treatment has the most beneficial effect on the microstructure of bone in experimental tumor osteolysis. | Journal of bone and mineral metabolism 20070101 |
| Clinical usefulness of bisphosphonates in oncology: treatment of bone metastases, antitumoral activity and effect on bone resorption markers. | The International journal of biological markers 20070101 |
| A novel study investigating the therapeutic outcome of patients with lytic, mixed and sclerotic bone metastases treated with combined radiotherapy and ibandronate. | Clinical & experimental metastasis 20070101 |
| Safety considerations with bisphosphonates for the treatment of osteoporosis. | Drug safety 20070101 |
| A review of bone pain relief with ibandronate and other bisphosphonates in disorders of increased bone turnover. | Clinical and experimental rheumatology 20070101 |
| [Does ibandronate (Bonviva) have an impact on non-vertebral fractures?]. | Reumatizam 20070101 |
| Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal females. | International journal of clinical pharmacology and therapeutics 20061201 |
| Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. | Current medical research and opinion 20061201 |
| Bisphosphonates. | Annals of the New York Academy of Sciences 20061201 |
| Compliance with treatment for osteoporosis. | Lancet (London, England) 20061111 |
| Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate. | Kidney international 20061101 |
| Bisphosphonates prevent experimental vascular calcification: Treat the bone to cure the vessels? | Kidney international 20061101 |
| [Ibandronate (Bonviva) in the treatment of postmenopausal osteoporosis]. | Revue medicale de Liege 20061101 |
| Ibandronate (boniva) offers new options for osteoporosis. | The Nurse practitioner 20061001 |
| Clinical utility of a pharmacostatistical model for ibandronate in postmenopausal osteoporosis. | Current drug metabolism 20061001 |
| Parathyromatosis and the challenge of treatment. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20060901 |
| [DVO guideline 2006. What changes have there been in the diagnosis, prevention and treatment of osteoporosis?]. | Zeitschrift fur Rheumatologie 20060901 |
| Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. | International journal of clinical practice 20060801 |
| Rinsing morcellised bone grafts with bisphosphonate solution prevents their resorption. A prospective randomised double-blinded study. | The Journal of bone and joint surgery. British volume 20060801 |
| New drugs 06, part II. | Nursing 20060801 |
| Intravenous ibandronate (Boniva). | The Medical letter on drugs and therapeutics 20060801 |
| Local bioavailability and distribution of systemically (parenterally) administered ibandronate in the infarcted femoral head. | Bone 20060701 |
| Bone marker response in chronic diffuse sclerosing osteomyelitis treated with intravenous ibandronate. | Annals of the rheumatic diseases 20060701 |
| Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results. | European journal of cancer care 20060701 |
| Osseointegration of cementless implants with different bisphosphonate regimens. | Clinical orthopaedics and related research 20060601 |
| Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. | Arthritis and rheumatism 20060601 |
| Less frequent dosing of bisphosphonates in osteoporosis: focus on ibandronate. | Current medical research and opinion 20060601 |
| Fracture prevention in postmenopausal women. | Clinical evidence 20060601 |
| Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. | Annals of the rheumatic diseases 20060501 |
| Extracellular matrix changes in knee joint cartilage following bone-active drug treatment. | Cell and tissue research 20060501 |
| Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy. | Pharmacotherapy 20060501 |
| What's new in clinical pharmacology and therapeutics. | WMJ : official publication of the State Medical Society of Wisconsin 20060501 |
| Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety. | Maturitas 20060420 |
| Adherence, patient preference and dosing frequency: understanding the relationship. | Bone 20060401 |
| Beyond daily dosing: clinical experience. | Bone 20060401 |
| Ibandronate: pharmacology and preclinical studies. | Bone 20060401 |
| Once-monthly dosing: an effective step forward. | Bone 20060401 |
| Preventing osteoporosis-related fractures: an overview. | The American journal of medicine 20060401 |
| Injectable drug approved for osteoporosis. | Health news (Waltham, Mass.) 20060401 |
| Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen. | Clinical therapeutics 20060401 |
| Modeling of serum C-telopeptide levels with daily and monthly oral ibandronate in humans. | Annals of the New York Academy of Sciences 20060401 |
| Drug insight: Bisphosphonates for postmenopausal osteoporosis. | Nature clinical practice. Endocrinology & metabolism 20060401 |
| Enthalpy versus entropy-driven binding of bisphosphonates to farnesyl diphosphate synthase. | Journal of the American Chemical Society 20060322 |
| [Therapy of hypercalcemia with ibandronate in case of acute renal failure]. | Der Internist 20060301 |
| Ibandronate treatment for osteoporosis: rationale, preclinical, and clinical development of extended dosing regimens. | Current osteoporosis reports 20060301 |
| A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20060201 |
| Independent pathways in the modulation of osteoclastic resorption by intermediates of the mevalonate biosynthetic pathway: the role of the retinoic acid receptor. | Bone 20060201 |
| Strategies for the prevention and treatment of osteoporosis during early postmenopause. | American journal of obstetrics and gynecology 20060201 |
| Rapid pain relief and remission of sternocostoclavicular hyperostosis after intravenous ibandronate therapy. | Journal of bone and mineral metabolism 20060101 |
| Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines. | Breast cancer research : BCR 20060101 |
| [Ibandronate once a month]. | Medizinische Monatsschrift fur Pharmazeuten 20060101 |
| Ibandronic acid: a review of its use in the treatment of bone metastases of breast cancer. | Drugs 20060101 |
| Ibandronate: the evolution of a once-a-month oral therapy for postmenopausal osteoporosis. | Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 20060101 |
| Rapid infusion of ibandronate in lung cancer patients with bone metastases. | Anticancer research 20060101 |
| Treating osteoporosis with bisphosphonates and addressing adherence: a review of oral ibandronate. | Drugs 20060101 |
| Sequence- and concentration-dependent effects of acute and long-term exposure to the bisphosphonate ibandronate in combination with single and multiple fractions of ionising radiation doses in human breast cancer cell lines. | Clinical & experimental metastasis 20060101 |
| Intravenous ibandronate: in the treatment of osteoporosis. | Drugs 20060101 |
| Ibandronate: its role in metastatic breast cancer. | The oncologist 20060101 |
| Ibandronate for the treatment of hypercalcemia or nephrocalcinosis in patients with multiple myeloma and acute renal failure: Case reports. | Acta haematologica 20060101 |
| Non-ulcerating calcific uremic arteriolopathy skin lesion treated successfully with intravenous ibandronate. | Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 20060101 |
| Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. | Drug safety 20060101 |
| Intravenous ibandronate in the treatment of osteoporosis: profile report. | Drugs & aging 20060101 |
| Safety of oral ibandronate in the treatment of bone metastases from breast cancer : long-term follow-up experience. | Clinical drug investigation 20060101 |
| Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial. | Clinical drug investigation 20060101 |
| [The role of ibandronate in the daily oncological practice]. | Magyar onkologia 20060101 |
| [Ibandronate]. | Reumatizam 20060101 |
| Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy. | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20051201 |
| Effective and rapid treatment of painful localized transient osteoporosis (bone marrow edema) with intravenous ibandronate. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20051201 |
| Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates? | Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery 20051201 |
| Newer drug treatments: their effects on fracture prevention. | Best practice & research. Clinical rheumatology 20051201 |
| Acute renal effects of intravenous bisphosphonates in the rat. | Basic & clinical pharmacology & toxicology 20051201 |
| Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). | Current medical research and opinion 20051201 |
| Highlights From ECCO 13-The European Cancer Conference Paris, France October 30 to November 3, 2005. | Clinical breast cancer 20051201 |
| Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. | Bone 20051101 |
| High dosage treatment of nitrogen-containing bisphosphonate ibandronate is required for osseointegration of cementless metal implants. | Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association 20051101 |
| S0307. Phase III trial of bisphosphonates as adjuvant therapy for primary breast cancer. | Clinical advances in hematology & oncology : H&O 20051101 |
| Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis. | Bone 20051001 |
| Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age. | The Journal of rheumatology 20051001 |
| Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis. | Expert opinion on pharmacotherapy 20051001 |
| Review of treatment modalities for postmenopausal osteoporosis. | Southern medical journal 20051001 |
| Ibandronate: efficacy in the treatment of metastatic bone disease. | Future oncology (London, England) 20051001 |
| Analytical methods for the quantification of ibandronate in body fluids and bone. | Journal of pharmaceutical and biomedical analysis 20050901 |
| Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study. | The Journal of clinical endocrinology and metabolism 20050901 |
| The bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats. | Bone 20050801 |
| Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20050801 |
| Ibandronate (Boniva): a new oral bisphosphonate. | Obstetrics and gynecology 20050801 |
| Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom. | Clinical therapeutics 20050801 |
| A new option for osteoporosis. | The Johns Hopkins medical letter health after 50 20050701 |
| New therapeutic agents for the treatment of bone diseases. | Expert opinion on biological therapy 20050601 |
| Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials. | Clinical breast cancer 20050601 |
| First once-a-month osteoporosis pill approved. | Harvard women's health watch 20050601 |
| A bright future for osteoporosis treatment. | Drug news & perspectives 20050601 |
| Longer-lasting osteoporosis drugs sought. | JAMA 20050525 |
| Bisphosphonates in breast cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20050501 |
| Changes in bone structure after augmentation cystoplasty in chronic uraemic rats. | BJU international 20050501 |
| The issue of renal safety of zoledronic acid from a nephrologist's point of view. | The oncologist 20050501 |
| 'Safety and convenience of a 15-minute infusion of zoledronic acid': not so safe. | The oncologist 20050501 |
| New drugs and dosage forms. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20050501 |
| Ibandronate (Boniva): a new oral bisphosphonate. | The Medical letter on drugs and therapeutics 20050425 |
| Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. | Annals of oncology : official journal of the European Society for Medical Oncology 20050301 |
| Ibandronate for prevention of femoral head deformity after ischemic necrosis of the capital femoral epiphysis in immature pigs. | The Journal of bone and joint surgery. American volume 20050301 |
| Oral antiresorptive therapy. | Current rheumatology reports 20050301 |
| Rapid prevention of vertebral fractures associated with osteoporosis. | Orthopedics 20050301 |
| Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. | Current medical research and opinion 20050301 |
| Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20050201 |
| Explicit solutions for a class of indirect pharmacodynamic response models. | Computer methods and programs in biomedicine 20050201 |
| Ibandronate in metastatic bone disease: a review of preclinical data. | Anti-cancer drugs 20050201 |
| Oral ibandronic acid. | IDrugs : the investigational drugs journal 20050201 |
| [Ibandronate as a new therapeutic agent for osteoporosis]. | Clinical calcium 20050101 |
| The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications. | Oncology 20050101 |
| Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis. | Treatments in endocrinology 20050101 |
| [Monthly tablet]. | Krankenpflege Journal 20050101 |
| New drugs: entecavir, ibandronate sodium, and pegaptanib sodium. | Journal of the American Pharmacists Association : JAPhA 20050101 |
| Optimizing administration of bisphosphonates in women with postmenopausal osteoporosis. | Treatments in endocrinology 20050101 |
| Bisphosphonate treatment does not affect serum levels of osteoprotegerin and RANKL in hypercalcemic cancer patients. | Anticancer research 20050101 |
| [Postmenopausal osteoporosis]. | Krankenpflege Journal 20050101 |
| Efficacy of ibandronate in metastatic bone disease: review of clinical data. | The oncologist 20050101 |
| Renal safety of ibandronate. | The oncologist 20050101 |
| Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review. | Current pharmaceutical design 20050101 |
| Once-monthly ibandronate. | Treatments in endocrinology 20050101 |
| High bone-binding capacity of ibandronate in hemodialysis patients. | International journal of clinical pharmacology research 20050101 |
| [Zoledronic acid and bone pathology in the course of neoplasia. Part I]. | Tumori 20050101 |
| [Monthly tablet in postmenopausal osteoporosis]. | Krankenpflege Journal 20050101 |
| Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy. | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20041201 |
| A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. | British journal of clinical pharmacology 20041201 |
| Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease. | Expert review of anticancer therapy 20041201 |
| Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy. | Seminars in oncology 20041201 |
| [Clinical trial on ibandronate in patients with tumor-associated hypercalcemia]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20041201 |
| Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials. | Clinical therapeutics 20041201 |
| Intermittent ibandronate preserves bone quality and bone strength in the lumbar spine after 16 months of treatment in the ovariectomized cynomolgus monkey. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20041101 |
| Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. | Oncology reports 20041101 |
| Efficacy and safety of ibandronate in the treatment of neoplastic bone disease. | Expert opinion on pharmacotherapy 20041101 |
| Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20041001 |
| Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. | Pain 20041001 |
| The efficacy and safety of oral ibandronate in the treatment of metastatic bone disease in patients with breast cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20041001 |
| Targeting Breast Cancer with Care. Proceedings of a meeting. Prague, Czech Republic, February 2004. | Seminars in oncology 20041001 |
| Ibandronate reduces skeletal morbidity in patients with breast cancer. | Seminars in oncology 20041001 |
| Ibandronate in metastatic bone pain. | Seminars in oncology 20041001 |
| Managing metastatic bone disease: three case studies. | Seminars in oncology 20041001 |
| The RIB trial. | Clinical oncology (Royal College of Radiologists (Great Britain)) 20041001 |
| Systemic and local ibandronate enhance screw fixation. | Journal of orthopaedic research : official publication of the Orthopaedic Research Society 20040901 |
| Ibandronate: a clinical pharmacological and pharmacokinetic update. | Journal of clinical pharmacology 20040901 |
| Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040901 |
| [Therapy of painful bone metastases in patients with prostate carcinoma. The AP 32/02 Study of the AUO]. | Der Urologe. Ausg. A 20040901 |
| In vitro toxicity of bisphosphonates on human neuroblastoma cell lines. | Anti-cancer drugs 20040901 |
| Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20040801 |
| Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone. | Bone 20040701 |
| Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. | European journal of cancer (Oxford, England : 1990) 20040701 |
| Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20040601 |
| Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB-231 cells. | International journal of oncology 20040501 |
| Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20040501 |
| Ibandronate and prevention of postmenopausal osteoporosis. | Annals of the rheumatic diseases 20040501 |
| Bisphosphonates and reduction of skeletal events in patients with bone metastatic breast cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20040501 |
| Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. | Annals of oncology : official journal of the European Society for Medical Oncology 20040501 |
| Efficacy and safety of ibandronate given by intravenous injection once every 3 months. | Bone 20040501 |
| Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. | Bone 20040501 |
| [Bone metastases in breast carcinoma. Bisphosphonate protects from complications]. | MMW Fortschritte der Medizin 20040401 |
| Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. | British journal of cancer 20040322 |
| Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20040301 |
| Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. | Annals of oncology : official journal of the European Society for Medical Oncology 20040301 |
| Nephrotoxicity of third-generation, intravenous bisphosphonates. | Toxicology 20040301 |
| [Ibandronate]. | Nihon rinsho. Japanese journal of clinical medicine 20040201 |
| Serum levels of the fetuin-mineral complex correlate with artery calcification in the rat. | The Journal of biological chemistry 20040116 |
| Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20040101 |
| Safety and convenience of a 15-minute infusion of zoledronic acid. | The oncologist 20040101 |
| New model for simulation of fracture repair in full-grown beagle dogs: model characterization and results from a long-term study with ibandronate. | Journal of pharmacological and toxicological methods 20040101 |
| [Ibandronate: keep life in motion]. | Tumori 20040101 |
| [Oral and parenteral forms of aminobisphosphonate]. | Krankenpflege Journal 20040101 |
| [AIOM Conference 2004. Endocrine therapy and management of patients with bone metastasis of breast cancer]. | Tumori 20040101 |
| [ESMO Conference 2004. Ibandronate in the treatment of bone metastasis]. | Tumori 20040101 |
| Ibandronate improves hyperphosphatemia in dialysis patients with hyperparathyroidism. | International urology and nephrology 20040101 |
| Injectable drug dampens bone loss. | Health news (Waltham, Mass.) 20031201 |
| Is ibandronate effective in multiple myeloma? | European journal of haematology 20031201 |
| Use of highly potent bisphosphonates in the treatment of osteoporosis. | Current osteoporosis reports 20031201 |
| Bisphosphonates in children with bone diseases. | The New England journal of medicine 20031120 |
| Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: model characterisation and in vivo effects of ibandronate on tumour growth. | International journal of cancer 20031110 |
| Ibandronate: new options in the treatment of osteoporosis. | Drugs of today (Barcelona, Spain : 1998) 20031101 |
| Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women. | Annals of the rheumatic diseases 20031001 |
| The effects of three-month intravenous ibandronate on bone mineral density and bone remodeling in Klinefelter's syndrome: the influence of vitamin D deficiency and hormonal status. | Bone 20031001 |
| Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. | The Journal of clinical endocrinology and metabolism 20031001 |
| Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20031001 |
| The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. | Toxicology 20030930 |
| Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. | Annals of oncology : official journal of the European Society for Medical Oncology 20030901 |
| Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20030801 |
| Oral weekly ibandronate prevents bone loss in postmenopausal women. | Journal of internal medicine 20030801 |
| Injectable bisphosphonates in the treatment of postmenopausal osteoporosis. | Aging clinical and experimental research 20030801 |
| Intravenous ibandronate in men with osteoporosis: an open pilot study over 2 years. | Journal of endocrinological investigation 20030801 |
| The bisphosphonate ibandronate stimulates reverse cholesterol transport out of monocytoid cells by enhanced ABCA1 transcription. | Biochemical and biophysical research communications 20030718 |
| Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20030701 |
| Lytic bone lesions in human neuroblastoma xenograft involve osteoclast recruitment and are inhibited by bisphosphonate. | Cancer research 20030615 |
| Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis. | Rheumatology (Oxford, England) 20030601 |
| Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens. | Bone 20030601 |
| Ibandronate: a potent new bisphosphonate in the management of postmenopausal osteoporosis. | International journal of clinical practice 20030601 |
| Effects of ibandronate on inflammation in mouse antigen-induced arthritis. | Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20030501 |
| The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast. | Bone 20030401 |
| Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate. | Alimentary pharmacology & therapeutics 20030315 |
| Review of ibandronate in the treatment of osteoporosis. | Expert opinion on pharmacotherapy 20030301 |
| Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20030201 |
| Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. | Bone 20030101 |
| Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma. | European journal of haematology 20030101 |
| Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies. | Clinical therapeutics 20030101 |
| Bisphosphonates in the management of metastatic prostate cancer. | Oncology 20030101 |
| [Effects of ibandronate on the osteopenia process in tail-suspended rats]. | Aviakosmicheskaia i ekologicheskaia meditsina = Aerospace and environmental medicine 20030101 |
| Treatment of hypercalcemia of malignancy with bisphosphonates. | Seminars in oncology 20021201 |
| Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. | Cancer research 20021115 |
| The amino bisphosphonate ibandronate prevents calciphylaxis in the rat at doses that inhibit bone resorption. | Calcified tissue international 20021001 |
| The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. | Breast cancer research and treatment 20021001 |
| Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. | The Journal of rheumatology 20021001 |
| Effect of transplantation on bone: osteoporosis after liver and multivisceral transplantation. | Transplantation proceedings 20020901 |
| Elimination of intravenously administered ibandronate in patients on haemodialysis: a monocentre open study. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20020701 |
| Novel therapeutic options for osteoporosis. | Current opinion in rheumatology 20020701 |
| Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products. | Annals of the rheumatic diseases 20020601 |
| Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. | Journal of endocrinological investigation 20020601 |
| Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020501 |
| Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats. | The Journal of rheumatology 20020501 |
| Bisphosphonates for prevention of postmenopausal osteoporosis. | Danish medical bulletin 20020201 |
| Ibandronate treatment decreases the effects of tumor-associated lesions on bone density and strength in the rat. | Bone 20020101 |
| Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. | Bone 20020101 |
| Safety and efficacy of the new bisphosphonate ibandronate in the management of bone metastasis following rapid infusion. | In vivo (Athens, Greece) 20020101 |
| Ibandronate in the treatment of prostate cancer associated painful osseous metastases. | Prostate cancer and prostatic diseases 20020101 |
| Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20011001 |
| [Radiotherapy and bisphosphonate therapy in bone metastases of prostate carcinoma]. | Praxis 20010920 |
| Effect of ibandronate on bone loss and renal function after kidney transplantation. | Journal of the American Society of Nephrology : JASN 20010701 |
| The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. | Cancer research 20010601 |
| Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. | Arteriosclerosis, thrombosis, and vascular biology 20010501 |
| Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma. | Experimental hematology 20010401 |
| Bisphosphonates induce breast cancer cell death in vitro. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20001101 |
| Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 19980401 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.